CytoReason built a machine learning platform that can quantify a person’s immune system in order to better understand disease responses.

CytoReason said it plans to present insights on the top drug targets to provide new therapeutic options for IBD patients.

Professor Regina Barzilay is being honored for her work using ML models to detect and predict cancer, and accelerate drug development.

Founded in 2016, CytoReason already has partnerships with top global pharmaceutical companies.

The company's propriety platform combines scientific and experimental data for immune system simulations applicable to cancer immunotherapy, and autoimmune, neurodegenerative and infectious disease research.

Israeli data researchers, including Dr. Kira Radinsky, say they developed a system that will significantly shorten drug development time and reduce costs.